# KLOW peptide — The Four-Peptide Research Record, Catalogued > KLOW peptide is a research-only co-formulation of four peptides — KPV, GHK-Cu, BPC-157 and TB-500. A catalogue of the component literature, cited per constituent, with the unrecorded blend study marked plainly. Four peptides — KPV, GHK-Cu, BPC-157 and TB-500 — inscribed as four distinct columns of the literature, each finding cited to the constituent it belongs to, the one unwritten chapter marked plainly. ## Before the details The KLOW peptide is not one substance. It is four research peptides — KPV, GHK-Cu, BPC-157 and TB-500 — dissolved together in one vial. The four stay separate molecules; they do not fuse into a new one. Each was studied on its own, mostly in cells and animals, for a different part of healing: calming inflammation, building the skin's framework, growing new blood vessels and helping cells move to close a wound. The vial pairs them on the idea that those four jobs work together. Here is the honest part: no proper study has ever tested the four mixed together. Every claim that they add up is an educated guess from the single-peptide research, not direct proof. None of the four is FDA-approved, and the mix is sold for laboratory use only. What people report — including the downsides — is on [the effects page](/effects), and you can read [what the component research shows](/research) or compare [KLOW vs GLOW comparison](/klow-vs-glow). ## What is KLOW peptide? KLOW peptide is a co-formulation — four chemically distinct research peptides supplied in a single vial at fixed mass ratios. The four are KPV (a three-amino-acid fragment of a hormone called alpha-MSH, studied for calming inflammation), GHK-Cu (a copper-carrying tripeptide studied for collagen and gene expression), BPC-157 (a 15-amino-acid peptide studied in rodent tissue repair) and TB-500 (a short fragment of the protein thymosin beta-4, studied for cell movement and wound closure). They remain four separate molecules co-dissolved together — a co-formulation, not a single compound, and not a single FDA-approved product. No pharmacopeial KLOW exists; the mixture is supplied strictly as a research-chemical co-formulation. ## What the KLOW blend is The KLOW blend is a lyophilized (freeze-dried) mixture of four peptides at a fixed ratio, most often listed as an 80 mg total vial. The design logic is that the four occupy largely non-overlapping nodes of one tissue-repair network: KPV suppresses inflammatory transcription, GHK-Cu drives matrix synthesis and supplies copper for collagen crosslinking, BPC-157 drives the angiogenic pathway, and TB-500 sequesters G-actin to support cell migration. That rationale is drawn entirely from the single-component literature. No controlled in-vivo or human study has tested the four-peptide KLOW blend against monotherapy, any subset, or placebo, so every combination claim is a mechanistic extrapolation — not direct blend evidence. This catalogue marks that gap plainly rather than reading component findings as blend efficacy. ## What is in the 80 mg KLOW vial? The most widely listed research-vial composition is an 80 mg total of GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. GHK-Cu is the mass-dominant component at about 62.5% of the vial by mass — which is also why a reconstituted KLOW solution can read blue, since GHK-Cu carries a copper(II) ion and copper(II) complexes are characteristically blue. The four peptides remain separate molecules co-dissolved at fixed ratios. Each carries its own molecular identity: KPV (MW 342.44 Da), GHK-Cu (MW 402.92 Da), BPC-157 (MW 1419.53 Da) and TB-500 (Ac-LKKTETQ, MW 889.02 Da). There is no single CAS, UNII or PubChem identifier for the mixture, because a mixture is not a defined substance. ## What does the KLOW peptide do? By design the KLOW peptide pairs four arms of one repair network. KPV is the anti-inflammatory arm: at nanomolar concentrations it inhibits NF-kappaB (a master switch for inflammatory genes) and MAP-kinase signaling and reduces pro-inflammatory cytokine output [3]. GHK-Cu is the matrix arm: it stimulates collagen and proteoglycan synthesis and modulates a large fraction of assayed genes in fibroblasts [4][5]. BPC-157 is the tissue-repair arm: in a transected rat Achilles tendon it accelerated healing across biomechanical, functional and microscopic measures [2]. TB-500 is the cell-migration arm, carrying the actin-binding motif of thymosin beta-4, the protein whose full-length form accelerated wound re-epithelialization in rats [1]. What the combination actually does is unproven — there is no blend study. ## Do the peptides in KLOW have any research on hair growth? Two of KLOW's components carry hair-follicle research. Thymosin beta-4 — the protein the TB-500 fragment is derived from — activated hair-follicle bulge stem cells and increased hair growth in rats and mice at nanomolar concentrations, raising MMP-2 expression [6][9]. Copper-tripeptide complexes related to GHK-Cu stimulated follicle activity in C3H mice [7], and AHK-Cu, a close copper-tripeptide analog of GHK-Cu, elongated human hair follicles ex vivo and reduced dermal-papilla-cell apoptosis at picomolar-to-nanomolar concentrations [8]. This is [hair-follicle research on the KLOW peptides](/) at the component level and mostly preclinical; the KLOW blend itself has never been tested for hair growth. Read more in [KLOW peptide benefits in the component research](/benefits-research). --- A monumental catalogue of the four-peptide KLOW record, inscribed per constituent with the unwritten blend study left a plainly marked lacuna — not a clinic, not an apothecary, not a prescription.